The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Epavudine     1-[(2S,4R,5S)-4-hydroxy-5...

Synonyms: Sebivo, Telbivudin, Tyzeka, Telbivudine, L-Thymidine, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Epavudine


High impact information on Epavudine


Chemical compound and disease context of Epavudine


Biological context of Epavudine

  • Also the 5'-triphosphate of beta-L-thymidine (beta-L-TTP) was shown to be a strong inhibitor of these two viral enzymes (IC50 = 0.46/1.0 microM) [13].
  • Values of Cmax, Tmax, and AUC were comparable when telbivudine was administered under fed and fasting conditions [14].
  • Oral absorption of telbivudine as measured by maximum plasma concentration (Cmax), time to reach Cmax (Tmax), and area under the plasma concentration-time curve (AUC(0-t) and AUC(0-infinity)) was not altered by food intake immediately before oral dosing [14].
  • We transformed synchronized mouse L-thymidine kinase deficient cells with a cloned thymidine kinase gene and carrier DNA at different times in the cell cycle [15].
  • Additionally, in preclinical animal toxicology studies, telbivudine showed no adverse side effects or adverse effects on mitochondrial function [16].

Associations of Epavudine with other chemical compounds


Gene context of Epavudine


Analytical, diagnostic and therapeutic context of Epavudine


  1. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Lai, C.L., Leung, N., Teo, E.K., Tong, M., Wong, F., Hann, H.W., Han, S., Poynard, T., Myers, M., Chao, G., Lloyd, D., Brown, N.A. Gastroenterology (2005) [Pubmed]
  2. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Lai, C.L., Lim, S.G., Brown, N.A., Zhou, X.J., Lloyd, D.M., Lee, Y.M., Yuen, M.F., Chao, G.C., Myers, M.W. Hepatology (2004) [Pubmed]
  3. Stereospecificity of human DNA polymerases alpha, beta, gamma, delta and epsilon, HIV-reverse transcriptase, HSV-1 DNA polymerase, calf thymus terminal transferase and Escherichia coli DNA polymerase I in recognizing D- and L-thymidine 5'-triphosphate as substrate. Focher, F., Maga, G., Bendiscioli, A., Capobianco, M., Colonna, F., Garbesi, A., Spadari, S. Nucleic Acids Res. (1995) [Pubmed]
  4. L-thymidine is phosphorylated by herpes simplex virus type 1 thymidine kinase and inhibits viral growth. Spadari, S., Maga, G., Focher, F., Ciarrocchi, G., Manservigi, R., Arcamone, F., Capobianco, M., Carcuro, A., Colonna, F., Iotti, S. J. Med. Chem. (1992) [Pubmed]
  5. Beta-L-thymidine 5'-triphosphate analogs as DNA polymerase substrates. Van Draanen, N.A., Tucker, S.C., Boyd, F.L., Trotter, B.W., Reardon, J.E. J. Biol. Chem. (1992) [Pubmed]
  6. Treating chronic hepatitis B: today and tomorrow. Borgia, G., Gentile, I. Current medicinal chemistry. (2006) [Pubmed]
  7. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Zhou, X.J., Fielman, B.A., Lloyd, D.M., Chao, G.C., Brown, N.A. Antimicrob. Agents Chemother. (2006) [Pubmed]
  8. Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Hernandez-Santiago, B., Placidi, L., Cretton-Scott, E., Faraj, A., Bridges, E.G., Bryant, M.L., Rodriguez-Orengo, J., Imbach, J.L., Gosselin, G., Pierra, C., Dukhan, D., Sommadossi, J.P. Antimicrob. Agents Chemother. (2002) [Pubmed]
  9. Kinetic studies with N2-phenylguanines and with L-thymidine indicate that herpes simplex virus type-1 thymidine kinase and thymidylate kinase share a common active site. Maga, G., Focher, F., Wright, G.E., Capobianco, M., Garbesi, A., Bendiscioli, A., Spadari, S. Biochem. J. (1994) [Pubmed]
  10. Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B. Xu, X.W., Chen, Y.G. HBPD INT (2006) [Pubmed]
  11. Telbivudine/Torcitabine Idenix/Novartis. Hodge, R.A. Current opinion in investigational drugs (London, England : 2000) (2004) [Pubmed]
  12. New and emerging treatment of chronic hepatitis B. Keeffe, E.B., Marcellin, P. Clin. Gastroenterol. Hepatol. (2007) [Pubmed]
  13. Newly synthesized L-enantiomers of 3'-fluoro-modified beta-2'-deoxyribonucleoside 5'-triphosphates inhibit hepatitis B DNA polymerases but not the five cellular DNA polymerases alpha, beta, gamma, delta, and epsilon nor HIV-1 reverse transcriptase. von Janta-Lipinski, M., Costisella, B., Ochs, H., Hübscher, U., Hafkemeyer, P., Matthes, E. J. Med. Chem. (1998) [Pubmed]
  14. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. Zhou, X.J., Lloyd, D.M., Chao, G.C., Brown, N.A. Journal of clinical pharmacology. (2006) [Pubmed]
  15. DNA-mediated gene transfer is more efficient during S-phase of the cell cycle. Giulotto, E., Israel, N. Biochem. Biophys. Res. Commun. (1984) [Pubmed]
  16. Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B. Han, S.H. Expert opinion on investigational drugs. (2005) [Pubmed]
  17. Lack of stereospecificity of suid pseudorabies virus thymidine kinase. Maga, G., Verri, A., Bonizzi, L., Ponti, W., Poli, G., Garbesi, A., Niccolai, D., Spadari, S., Focher, F. Biochem. J. (1993) [Pubmed]
  18. Current and future treatment of chronic hepatitis B. Arosemena, L.R., Cortes, R.A., Servin, L., Schiff, E.R. Minerva gastroenterologica e dietologica. (2005) [Pubmed]
  19. Telbivudine: a novel nucleoside analog for chronic hepatitis B. Kim, J.W., Park, S.H., Louie, S.G. The Annals of pharmacotherapy. (2006) [Pubmed]
  20. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Zhou, X.J., Lim, S.G., Lloyd, D.M., Chao, G.C., Brown, N.A., Lai, C.L. Antimicrob. Agents Chemother. (2006) [Pubmed]
  21. Telbivudine: an upcoming agent for chronic hepatitis B. Yuen, M.F., Lai, C.L. Expert review of anti-infective therapy. (2005) [Pubmed]
WikiGenes - Universities